Proton Therapy + Chemotherapy for Esophageal Cancer

Recruiting in Palo Alto (17 mi)

Overseen byJohn Plastaras, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Abramson Cancer Center of the University of Pennsylvania

No Placebo Group

Trial Summary

What is the purpose of this trial?Patients with esophageal cancer to be treated with concurrent preoperative proton therapy along with carboplatin and paclitaxel.

Eligibility Criteria

This trial is for adults over 18 with locally advanced esophageal cancer, specifically adenocarcinoma located below the carina. They must be fit for surgery and have good organ function, not be pregnant or nursing, and agree to use birth control if of childbearing potential. Tumors must not exceed certain sizes.

Inclusion Criteria

I am older than 18 years.

I can carry out all my usual activities without help.

Patients must be able to provide informed consent

+8 more

Exclusion Criteria

My primary tumor is larger than 8 cm long or 5 cm wide.

My primary tumor is located in the upper part of my lungs.

I have not had any cancer other than skin or thyroid cancer in the last 2 years.

+1 more

Participant Groups

The study tests increasing doses of preoperative proton beam radiotherapy combined with chemotherapy drugs Carboplatin and Paclitaxel in patients with esophageal cancer to see how well they tolerate it before surgery.

1Treatment groups

Experimental Treatment

Group I: Dose Escalation of Neoadjuvant Proton Radiotherapy in Esophageal CancerExperimental Treatment3 Interventions

Patients with esophageal cancer to be treated with concurrent preoperative chemoradiation with carboplatin and paclitaxel.

Carboplatin is already approved in United States, European Union, Canada for the following indications:

🇺🇸 Approved in United States as Paraplatin for: